10-Q/A: SS Innovations International Restates Financials, Cites Material Errors and Control Weaknesses

SS Innovations International restated its previously issued interim financial statements for the quarter ended March 31, 2024, due to material errors and identified material weaknesses in internal controls.

Summary

• SS Innovations International, Inc. restated its interim unaudited condensed consolidated financial statements for the three months ended March 31, 2024, and March 31, 2023.
• The restatement was due to errors in accounting for the merger transaction, functional reclassifications, revenue recognition for deferred payment sales, recognition of right of use assets and liabilities, and other adjustments.
• The company's management concluded that its disclosure controls and procedures and internal controls over financial reporting were not effective as of March 31, 2024, due to material weaknesses related to the accounting errors.
• The company is taking remedial actions to address these weaknesses, including enhancing the review process for significant transactions and implementing a new ERP system.
• The company had revenues of $3,637,693 for the three months ended March 31, 2024, compared to $370,120 for the three months ended March 31, 2023.
• The company incurred a net loss of $9,841,753 for the three months ended March 31, 2024, compared to a net loss of $1,313,016 for the three months ended March 31, 2023.
• The company's management is making efforts to raise further funding to scale up operations and meet its longer-term capital needs.
• The company is involved in legal proceedings in the Bahamas regarding a disputed shareholding in Otto Pvt Ltd, an indirect subsidiary.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financials, identification of material weaknesses in internal controls, and a significant net loss. While revenue increased, the overall financial health and control environment raise concerns.

Positives

• Revenue increased significantly to $3,637,693 for the quarter ended March 31, 2024, from $370,120 in the prior year, driven by increased sales of surgical robotic systems and instruments.
• The company is taking steps to remediate the identified material weaknesses in internal controls, including enhancing review processes and implementing a new ERP system.
• The company has been successful in raising capital through private offerings to finance its operations.

Negatives

• The company restated its financial statements due to material errors.
• The company identified material weaknesses in its internal controls over financial reporting.
• The company reported a significant net loss of $9,841,753 for the quarter ended March 31, 2024.
• The company's auditors were barred from appearing before the SEC, leading to a re-audit and internal review.
• The company's management concluded that its disclosure controls and procedures and internal controls over financial reporting were not effective as of March 31, 2024.

Risks

• The company's management has stated that these conditions raise substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on raising additional capital to fund its operations, and there is no assurance that it will be successful in doing so.
• The company is involved in legal proceedings in the Bahamas, which could result in financial losses and reputational damage.
• The company's disclosure controls and procedures and internal controls over financial reporting were not effective as of March 31, 2024, due to material weaknesses.

Future Outlook

The company expects to require substantial funds for scaling up its operations, for incurring capital expenditure to have its own in-house machining and tooling capacity and to continue to finance its research and development work in the field of surgical robotics.

Management Comments

• The company's management is making efforts to raise further funding to scale up operations and meet its longer-term capital needs.
• The company's management believes that there will be a favorable outcome in the legal case regarding the disputed shareholding in Otto Pvt Ltd.

Industry Context

The company operates in the surgical robotics industry, which is experiencing increasing adoption of robotically assisted surgeries and improved learning curves for robotic surgeons.

Comparison to Industry Standards

• Intuitive Surgical, a leader in the surgical robotics market, reported revenue of $1.93 billion for Q1 2024, showcasing the scale of established players.
• Stryker, another major player, has a diverse portfolio including robotics, with significant R&D investments, reflecting the industry's focus on innovation.
• Medtronic, while not solely focused on robotics, integrates robotic assistance into its broader surgical solutions, indicating a trend towards comprehensive surgical platforms.
• Globally, surgical robotics is seeing increased adoption, particularly in developed markets, with growth driven by technological advancements and demand for minimally invasive procedures.
• Compared to these established companies, SS Innovations is in an early stage of commercialization, with a focus on affordability and accessibility in markets like India.

Corporate Governance

Legal Proceedings

• In April 2024, an ex-shareholder of Otto Pvt Ltd. commenced litigation in the Bahamas, seeking legal confirmation that it holds 9,000 shares (approximately a 9% interest) in Otto.
• The Bahamian court has issued an interim order to maintain the status quo with respect to the 9,000 Otto shares and SSI-Indias assets during the pendency of the litigation.

Related Party Transactions

• The company raised $2,450,000 through a private offering of 7% One-Year Convertible Promissory Notes from two affiliates of $1,000,000 each.
• Receivable from related party amounting to $1,510,647 and $1,567,559 as at March 31, 2024 and December 31, 2023 respectively, represents proceeds of convertible promissory notes raised by the Company from the investors during the respective years, but collected by related entities on its behalf.

Stakeholder Impact

• Shareholders may experience dilution due to potential future capital raises.
• Employees may be affected by the company's efforts to remediate internal control weaknesses.
• Customers may be impacted by the company's ability to continue as a going concern and provide ongoing support for its products.
• Creditors may be at risk if the company is unable to obtain financing and meet its obligations.

Next Steps

• The company is implementing a new ERP system to address the identified material weaknesses.
• The company is enhancing the review process for significant transactions to ensure proper accounting treatment.
• The company is pursuing legal action in the Bahamas to confirm the cancellation of shares in Otto Pvt Ltd.
• The company plans to raise additional capital through further private or public offerings.

Key Dates

Keywords

restatement, financial statements, internal controls, material weaknesses, revenue, net loss, surgical robotic systems, SSi Mantra, going concern, legal proceedings, capital raise